Scarica l'app Stockscreener
56.25
0.76%
-0.43
Dopo l'orario di chiusura:
56.00
-0.25
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$56.68
Aprire:
$57.12
Volume 24 ore:
1.56M
Relative Volume:
0.63
Capitalizzazione di mercato:
$5.36B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-20.09
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-1.94%
1M Prestazione:
+7.08%
6M Prestazione:
+36.00%
1 anno Prestazione:
+28.48%
Intervallo 1D:
$55.65
$58.35
Intervallo di 1 settimana:
$54.41
$59.24
Portata 52W:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
56.25 | 5.40B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
12 Days of Investing: My Top 12 Stocks to Buy Before 2026 - The Motley Fool
Marex Group plc Invests $948,000 in CRISPR Therapeutics AG $CRSP - MarketBeat
Biomedical Crispr Gene Editing Market Set for Dynamic - openPR.com
Nikko Asset Management Americas Inc. Sells 125,618 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
2 Healthcare Stocks to Buy Ahead of the New Year - Finviz
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech
New York State Common Retirement Fund Increases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? - sharewise.com
Buy Rating for Crispr Therapeutics AG: Pediatric Market Potential and Long-term Growth Opportunities - TipRanks
Is CRISPR Therapeutics (CRSP) Turning Early CTX310 Signals Into a Durable Genetic Medicine Platform? - Sahm
Guggenheim Capital LLC Sells 37,778 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Norges Bank Invests $19.77 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG Stock Analysis and ForecastMarket Sentiment Indicators & High Profit Market Ideas - earlytimes.in
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Nigeria
(CRSP) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics (CRSP): Reassessing Valuation After Casgevy Approvals and Growing 2025 Revenue Expectations - Sahm
Jump Financial LLC Buys New Shares in CRISPR Therapeutics AG $CRSP - MarketBeat
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz
CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook - ts2.tech
State Board of Administration of Florida Retirement System Acquires New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG: Stock surge amid challenges - MSN
Crispr Therapeutics AG: Stock Surge Amid Challenges - TipRanks
Vertex's gene therapy shows promise in younger children with blood disorders - Reuters
50,250 Shares in CRISPR Therapeutics AG $CRSP Purchased by Philadelphia Trust Co. - MarketBeat
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown - MSN
Will CRISPR Therapeutics AG (1CG) stock return to pre crash levelsWeekly Trade Report & Weekly High Potential Stock Alerts - Newser
Is CRISPR Therapeutics AG stock a bargain at current levelsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Cathie Wood’s Buys And Rumors Aside, Here’s Why Crispr Therapeutics Is A Strong Buy (CRSP) - Seeking Alpha
CRISPR Therapeutics AG $CRSP Shares Bought by Legal & General Group Plc - MarketBeat
Rhumbline Advisers Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Will CRISPR Therapeutics AG stock continue upward momentumLayoff News & Weekly Top Stock Performers List - Newser
Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsMarket Volume Summary & Long Hold Capital Preservation Tips - Newser
How dovish Fed policy supports CRISPR Therapeutics AG (1CG) stockJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Will CRISPR Therapeutics AG (1CG) stock outperform benchmarksMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Will CRISPR Therapeutics AG (1CG) stock outperform value peers2025 Price Targets & High Accuracy Trade Alerts - Newser
Will CRISPR Therapeutics AG (1CG) stock hit analyst forecastsMarket Sentiment Summary & AI Based Trade Execution Alerts - Newser
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - MSN
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP) - Seeking Alpha
The Best CRISPR Companies for 2025 - The Motley Fool
Crispr Therapeutics (CRSP) Gains Amid Takeover Speculation - GuruFocus
Crispr Therapeutics pares loss amid takeover speculation (CRSP:NASDAQ) - Seeking Alpha
Inflation Data: Can SGBX stock maintain operating marginsMarket Performance Recap & Detailed Earnings Play Alerts - BỘ NỘI VỤ
Crispr Therapeutics (CRSP) Shares React to M&A Rumor - GuruFocus
Crispr Therapeutics rumor highlighted in Betaville blog - TipRanks
Loomis Sayles & Co. L P Has $41.68 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors - MSN
West Family Investments Inc. Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):